Medical Advocates
Cobicistat((GS-9350) |
Last
Update:
October 01, 2017
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader |
|
|
-
Inhibition of human cytochromes P450 in vitro by ritonavir
and cobicistat.
Hossain MA, Tran T, Chen T,
et
al
J
Pharm Pharmacol. 2017 Sep 29.
Abstract
-
Effect of cobicistat on tenofovir disoproxil fumarate (TDF):
what is true for TAF may also be true for TDF.
Cattaneo D, Minisci D, Baldelli S, et al
J Acquir Immune Defic Syndr.
2017 Sep 25.
Abstract
-
Cobicistat Versus Ritonavir: Similar Pharmacokinetic
Enhancers But Some Important Differences.
Tseng A, Hughes CA, Wu J,
et al
Ann Pharmacother. 2017 Jun
1:1060028017717018
Abstract
-
Simplification to single-tablet regimen of elvitegravir, cobicistat,
emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease
inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96
results of STRATEGY-PI.
Arribas JR, DeJesus E, van Lunzen J, et al
HIV Clin Trials. 2017 May 30:
Abstract
-
Right hip and bilateral shoulder capsulitis in
an HIV-infected individual treated with elvitegravir and cobicistat.
Al Tabaa O, Audren V, Hayton E, et al
AIDS.
2017 May 15;31(8):1195-1196.
Abstract
-
Once-daily atazanavir/cobicistat and darunavir/cobicistat
exposure over 72 h post-dose in plasma, urine and saliva: contribution to
drug pharmacokinetic knowledge.
Elliot ER, Amara A, Pagani N,
et ak
J Antimicrob Chemother. 2017
Apr 12
Abstract
-
Treating Older HIV-1-infected Subjects with Cobicistat-boosted
Darunavir in a 48-Week Phase 3 Trial.
Brown K, Patterson-Browning B, Liu C, et al
Rev Recent Clin Trials. 2017 Apr 7.
Abstract
-
Antiretroviral Boosting Agent Cobicistat Increases the
Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in
HIV-Negative Healthy Volunteers.
Gordon LA, Kumar P, Brooks KM, et alCirculation.
2016 Dec 6;
-
Iatrogenic Cushing's syndrome due to drug interaction between
glucocorticoids and the ritonavir or cobicistat containing HIV therapies.
Elliot ER, Theodoraki A, Jain LR,
et al
Clin Med (Lond). 2016
Oct;16(5):412-418.
Abstract
-
The development and application of a novel LC-MS/MS method for the measurement
of Dolutegravir, Elvitegravir and Cobicistat in human plasma.
Penchala SD, Fawcett S, Else L,
et
al
J Chromatogr B Analyt Technol Biomed Life Sci.
2016 May 27;1027:
Abstract
-
Cobicistat Significantly Increases Tacrolimus Serum
Concentrations in a Renal Transplant Recipient with Human Immunodeficiency Virus
Infection.
Han Z, Kane BM, Petty LA, et al
Pharmacotherapy. 2016 Apr 3.
Abstract
-
Population pharmacokinetic analysis of elvitegravir
and cobicistat in HIV-1-infected individuals.
Barceló C, Gaspar F, Aouri M, Panchaud
A, ert al
J Antimicrob Chemother.
2016 Mar 29.
-
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency
virus therapy.
von Hentig N.
HIV
AIDS (Auckl). 2015 Dec
22;8:1-16.
Abstract
-
Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs
with high genetic barrier to resistance.
Capetti A, Cossu MV, Rizzardini G.
Expert
Opin Pharmacother. 2015 Nov
27:1-14.
Abstract
-
Brief Report: Cobicistat Compared With Ritonavir as a
Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir
Disoproxil Fumarate: Week 144 Results.
Gallant JE, Koenig E, Andrade-Villanueva JF, et al
J
Acquir Immune Defic Syndr.
2015 Jul 1;69(3):338-340.
Abstract
-
Pharmacokinetic Enhancement in HIV Antiretroviral Therapy: A Comparison of
Ritonavir and Cobicistat.
Renjifo B, van Wyk J, Salem AH,
et al
AIDS Rev. 2015 Jan-Mar;17(1):37-46.
Abstract
-
Switching from ritonavir to cobicistat in HIV patients with
renal impairment who are virologically suppressed on a protease inhibitor.
Fisher M, McDonald C, Moyle G, Martorell C, et al
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):19824
Abstract
-
Cobicistat : a new opportunity in the treatment of HIV disease?
Capetti A, Rizzardini G.
Expert Opin Pharmacother.
2014 May 12:1-10
Abstract
-
Contribution of the organic anion transporter OAT2 to the renal active
tubular secretion of creatinine and mechanism for serum creatinine
elevations caused by cobicistat.
Lepist EI, Zhang X, Hao J,
et al
Kidney Int.
2014 Mar 19.
Abstract
-
Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir
and Darunavir in Patients with HIV-1 Infection
Deeks ED.
Drugs. 2013 Dec 17.
Abstract
-
Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease
and Integrase Inhibitors.
Nathan B, Bayley J,
Waters L, Post FA.
Infect Dis Ther. 2013 Dec;2(2):111-22.
Abstract
-
Evaluation of the Effect of Cobicistat on the In Vitro Renal
Transport and Cytotoxicity Potential of Tenofovir.
Stray KM, Bam RA, Birkus G,
et al
Antimicrob Agents Chemother. 2013 Jul
29
Abstract
-
Cobicistat, a pharmacoenhancer for HIV treatments.
Temesgen Z.
Drugs Today (Barc). 2013
Apr;49(4):233-7.
Abstract
-
Cobicistat Versus Ritonavir as a Pharmacoenhancer of
Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in
Treatment-Naive HIV Type 1-Infected Patients: Week 48 Results.
Gallant JE, Koenig E, Andrade-Villanueva J, et a
al
J Infect Dis. 2013 Apr 19.
Abstract
-
Cobicistat: A New Boost for the Treatment of Human
Immunodeficiency Virus Infection.
Shah BM, Schafer JJ, Priano J, Squires KE
Pharmacotherapy.
2013 Mar 7.
Abstract
-
Cobicistat boosts the intestinal absorption of transport
substrates including HIV protease inhibitors and GS-7340 in vitro.
Lepist EI, Phan TK, Roy A,et
al
Antimicrob Agents Chemother.
2012 Jul 30.
Abstract
-
The elvitegravir Quad pill: the first once-daily
dual-target anti-HIV tablet.
Marchand C.
Expert Opin Investig Drugs.
2012 Jul;21(7):901-4.
Abstract
-
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir
disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated
emtricitabine and tenofovir disoproxil fumarate for initial treatment of
HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority
trial.
DeJesus E, Rockstroh JK, Henry K, et al
Lancet.
2012 Jun 30;379(9835):2429-38.
Abstract
-
Effect of Cobicistat on Glomerular Filtration Rate in
Subjects with Normal and Impaired Renal Function.
German P, Liu HC, Szwarcberg J, Hepner M,
J Acquir Immune Defic Syndr.
2012 Jun 22.
Abstract
-
Phase 2 study of cobicistat versus ritonavir each with once-daily
atazanavir and fixed-dose emtricitabine/tenofovir df in the initial
treatment of HIV infection.
Elion R, Cohen C, Gathe J, et al
AIDS.
2011 Sep 24;25(15):1881-6.
-
Phase 2 Study of Cobicistat versus Ritonavir each with
Atazanavir plus Fixed-Dose Emtricitabine/Tenofovir DF in the Initial
Treatment of HIV Infection.
Elion R, Cohen C,
Gathe J, et al
AIDS. 2011 Aug 1
Abstract
-
Randomized, phase 2 evaluation of two single-tablet
regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for
the initial treatment of HIV infection.
Cohen C, Elion R, Ruane P,
et al
AIDS.
2011 Mar 27;25(6):F7-12.
Abstract
-
Pharmacokinetics and bioavailability of an integrase and
novel pharmacoenhancer-containing single-tablet fixed-dose combination
regimen for the treatment of HIV.
German P, Warren D, West S,
et al
J Acquir Immune Defic Syndr. 2010
Nov 1;55(3):323-9.
Abstract
-
Pharmacokinetics and pharmacodynamics of GS-9350: a novel
pharmacokinetic enhancer without anti-HIV activity.
Mathias AA, German P, Murray BP,
et al
Clin Pharmacol Ther. 2010
Mar;87(3):322-9.
Abstract
|
|
XIX International AIDS Conference
|
-
Cobicistat versus
ritonavir as pharmacoenhancers in combination with atazanavir plus tenofovir
disoproxil fumarate/emtricitabine: phase 3 randomized, double blind,
active-controlled trial, week 48 results
J. Gallant, E. Koenig, J. Andrade-Villanueva, et al
Abstract
-
Analysis of efficacy
by baseline viral load: phase 3 study comparing
elvitegravir/cobicistat/emtricitabine/tenofovir DF (quad) versus
ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment-naïve
HIV-1-positive subjects: week 48 results
E. DeJesus, J. Rockstroh, K. Henry, et al
-
Analysis of
efficacy by baseline HIV RNA: week 48 results from a phase 3 study of
elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to
efavirenz/emtricitabine/tenofovir DF in treatment-naïve HIV-1-positive
subjects
P. Sax, E. De Jesus, A. Mills,, et al
-
The
clinical and economic impact of a generic first-line antiretroviral
regimen in the U.S.
R.P. Walensky , P.E. Sax , Y.M.
Nakamura , et al
|
|
|
New
and Noteworthy
Elvitegravir/Tenofovir
DF/Emtricitabine/Cobicistat
Main
New/Newsworthy